生物制剂治疗脊柱关节炎的感染复发：一项单中心研究。 - Suppr

Suppr

超能文献

Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study.

作者信息

Modesti V, Ramonda R, Ortolan A, Lorenzin M, Lo Nigro A, Frallonardo P, Oliviero F, Campana C, Punzi L

出版信息

Scand J Rheumatol. 2012;41(6):490-1. doi: 10.3109/03009742.2012.698393. Epub 2012 Sep 18.

DOI:10.3109/03009742.2012.698393

PMID:22985209

Abstract

摘要

相似文献

Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study.生物制剂治疗脊柱关节炎的感染复发：一项单中心研究。

Scand J Rheumatol. 2012;41(6):490-1. doi: 10.3109/03009742.2012.698393. Epub 2012 Sep 18.

Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.使用肿瘤坏死因子α拮抗剂治疗25例继发性淀粉样变性的风湿性炎症性疾病患者。

Am J Med. 2005 May;118(5):552-6. doi: 10.1016/j.amjmed.2005.01.028.

Do TNF-blockers reduce or induce uveitis?

Rheumatology (Oxford). 2008 May;47(5):731-2. doi: 10.1093/rheumatology/ken091. Epub 2008 Mar 17.

Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.肿瘤坏死因子拮抗剂治疗强直性脊柱炎患者的关节外表现的临床和经济负担。

J Med Econ. 2012;15(6):1054-63. doi: 10.3111/13696998.2012.692341. Epub 2012 Jun 11.

Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.脊柱关节炎（包括银屑病关节炎）中抗肿瘤坏死因子治疗的最新进展。

Curr Opin Rheumatol. 2006 Jul;18(4):347-53. doi: 10.1097/01.bor.0000231901.19795.8a.

Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides.抗TNF药物治疗炎性关节炎的十年药物生存率

Drug Dev Res. 2014 Nov;75 Suppl 1:S38-41. doi: 10.1002/ddr.21192.

Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.强直性脊柱炎中的葡萄膜炎与肿瘤坏死因子阻断治疗

Ann Rheum Dis. 2008 May;67(5):729-30. doi: 10.1136/ard.2007.077370.

Treatment of non-radiographic axial spondyloarthritis: it is only the beginning.非放射学中轴型脊柱关节炎的治疗：这仅仅是个开始。

Ann Rheum Dis. 2013 Jun;72(6):789-90. doi: 10.1136/annrheumdis-2012-202908.

The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.肿瘤坏死因子-α基因-308位点多态性可预测类风湿关节炎和脊柱关节炎患者对肿瘤坏死因子-α阻滞剂的治疗反应。

Rheumatology (Oxford). 2007 Jan;46(1):93-6. doi: 10.1093/rheumatology/kel175. Epub 2006 May 23.

Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study.在对英夫利昔单抗耐药或不耐受的强直性脊柱炎患者中，将治疗方案转换为每周一次给予50毫克依那西普：一项为期54周的研究结果

Arthritis Rheum. 2006 Oct 15;55(5):812-6. doi: 10.1002/art.22236.

引用本文的文献

Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies.生物制剂或靶向治疗药物治疗的银屑病关节炎和中轴型脊柱关节炎患者的感染发生率：随机对照试验、开放标签研究和观察性研究的系统评价和荟萃分析。

RMD Open. 2023 Sep;9(3). doi: 10.1136/rmdopen-2023-003064.

Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries.使用司库奇尤单抗治疗的感染风险是否高于使用 TNF 抑制剂？来自北欧国家的观察性研究。

Rheumatology (Oxford). 2023 Feb 1;62(2):647-658. doi: 10.1093/rheumatology/keac358.

Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study.抗 TNF-α、抗 IL-12/23 或抗 IL-17 药物治疗银屑病关节炎患者转换的预测因素：一项 15 年单中心真实世界研究。

Clin Rheumatol. 2021 Nov;40(11):4569-4580. doi: 10.1007/s10067-021-05799-0. Epub 2021 Jun 16.

Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis C.抗肿瘤坏死因子α在银屑病合并慢性丙型肝炎患者中的安全性和疗效

World J Clin Cases. 2016 Feb 16;4(2):49-55. doi: 10.12998/wjcc.v4.i2.49.

Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab.英夫利昔单抗治疗强直性脊柱炎患者的反应预测因素及药物生存期

BMC Musculoskelet Disord. 2015 Jul 24;16:166. doi: 10.1186/s12891-015-0620-4.

Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis.在接受银屑病免疫抑制治疗的HBsAg阴性、HBcAb阳性及丙型肝炎病毒（HCV）患者中，缺乏病毒再激活的证据。

BMC Gastroenterol. 2014 Dec 19;14:214. doi: 10.1186/s12876-014-0214-x.

Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients.抗TNF-α治疗对合并丙型肝炎病毒感染的银屑病关节炎患者的长期安全性：一项针对15例患者的回顾性观察性多中心研究

Clin Rheumatol. 2014 Feb;33(2):273-6. doi: 10.1007/s10067-013-2378-0. Epub 2013 Aug 24.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验